uniQure N.V. Investors Encouraged to Pursue Securities Fraud Legal Action

Opportunity for uniQure N.V. Investors to Join Class Action

uniQure N.V. (NASDAQ: QURE) investors have a significant opportunity to take part in a securities fraud lawsuit led by the Rosen Law Firm. Many shareholders who purchased shares during the class period from September 24, 2025, to October 31, 2025, may be entitled to seek compensation due to alleged misrepresentations made by the company.

Important Deadlines and Steps

The Rosen Law Firm urges impacted investors to note the April 13, 2026, deadline for appointing a lead plaintiff in this class action suit. If you are among those who purchased uniQure's ordinary shares during the specified period, you could become part of this prospective legal action. Importantly, potential participants can engage in this lawsuit without any out-of-pocket expenses through a contingency fee agreement, which means there are no upfront costs involved.

Joining the Class Action

Interested investors can easily join the class action by visiting the Rosen Law Firm’s website at rosenlegal.com, calling Phillip Kim, Esq. at 866-767-3653, or emailing their inquiry to [email protected]. Currently, the class action has already been filed, and any interested investors wishing to take on the role of lead plaintiff must submit their request to the court before the deadline of April 13, 2026. Being a lead plaintiff means representing the interests of other class members throughout the litigation process.

Why Choose Rosen Law Firm?

The Rosen Law Firm is renowned for its expertise in investor rights and its historical success in navigating securities class actions. Investors are strongly encouraged to select legal counsel with extensive experience, as many firms merely refer clients to others without directly litigating their cases. The Rosen Law Firm has established itself as a leading entity in this field, with notable achievements, including recording significant settlement figures in previous securities class actions. This reputation underscores their capability to effectively represent investors' interests.

In recent years, the firm has successfully recovered hundreds of millions of dollars for investors, providing significant confidence to those considering participation in this lawsuit. The firm's founding partner, Laurence Rosen, was recognized as a prominent figure in the plaintiffs' bar, showcasing their commitment to fighting for investor rights.

Details of the Allegations

The basis of the class action encompasses claims that uniQure misrepresented crucial information regarding its Pivotal Study—pertaining to its leading drug candidate aimed at treating Huntington's Disease. Allegedly, the company's representations to investors lacked sufficient substance, including the failure to disclose that certain designs of the Pivotal Study were not fully sanctioned by the U.S. Food and Drug Administration (FDA). Furthermore, allegations indicate that despite promising results from the study, uniQure would likely have to postpone its Biologics License Application (BLA) timeline to execute additional studies necessary for submission.

When these facts became evident, affected investors reportedly endured significant financial damage as a result of the misleading statements that were publicly circulated.

Take Action Now

Now is the time for investors affected by these claims to take action. With no class officially certified yet, individuals can either decide to remain passive class members or actively pursue joining the class action. Moreover, participation as a lead plaintiff is not a prerequisite for eligibility in any potential future recovery.

To stay updated with the latest developments regarding the class action, you can follow the Rosen Law Firm on various social media platforms such as LinkedIn, Twitter, and Facebook. If you believe you qualify, visit the Rosen Law Firm’s website today to get engaged. Time is of the essence, and taking timely action can offer investors the opportunity to seek the justice they deserve.